Document is current
Any future updates will be listed below
-
Authors
Lecca, Daniela
Hsueh, Shih-Chang
Luo, Weiming
Tweedie, David
Kim, Dong Seok
Baig, Abdul Mannan
Vargesson, Neil
Kim, Yu Kyung
Hwang, Inho
Kim, Sun
Hoffer, Barry J.
Chiang, Yung-Hsiao
Greig, Nigel H. https://orcid.org/0000-0002-3032-1468
-
Funding
Funding for this research was provided by:
The Intramural Research Program, National Institute on Aging, National Institutes of Health, USA (AG000994)
National Institutes of Health (R56 AG057028)
Technology Development Program of MSS, S. Korea (S2782046)
National Research Foundation (NRF) grant, S. Korea (2021M3A9G2015889)
Korea Research Institute of Bioscience and Biotechnology Research Initiative Program Grant
Sunny Brain Tumor and Brain Disease Research and Development Fund (106-5310-001-400)
TMU-CWRU(CTSC) Pilot Program (107-3805-004-400)
Ministry of Science and Technology, Taiwan (MOST 110-2314-B-038-106)
- License Information
-
More Information
Article History
Received: 11 January 2023
Accepted: 9 February 2023
First Online: 6 March 2023
Declarations
:
: Not applicable.
: All authors approve publication.
: TFBP and TFNBP are protected under US Patent Application No. 63/397,235 2022. NHG, WL, DL, DT are coinventors and have assigned their rights in entirety to NIA, NIH (i.e., the US Government). DSK is, likewise, a co-inventor and has assigned his rights to AevisBio Inc. NIA, NIH and AevisBio Inc., have a Cooperative Research and Development Agreement to develop novel thalidomide-like drugs for the treatment of neurological disorders involving excessive inflammation. DSK, YKK, IH, SK are employees and shareholders of AevisBio Inc. All other authors declare no conflict of interest. The funders had no role in the design of the studies; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
